LifeBridge Health, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
J Knee Surg. 2024 Jan;37(2):121-127. doi: 10.1055/s-0042-1760389. Epub 2023 Jan 19.
Over 25% of patients with rheumatoid arthritis (RA) are expected to undergo a joint replacement during their lifetime. Current practice guidelines recommend withholding biologic therapy 1 week prior to total hip arthroplasty, given its immunosuppressive effects. Most patients are on a regimen including biologic and nonbiologic therapy; however, the individual influences of these therapies are not well understood in the setting of total knee arthroplasty (TKA). Therefore, we sought to compare biologic, nonbiologic, and recipients of both types of therapy in patients with RA undergoing TKA. We specifically assessed (1) medical complications at 90 days; (2) surgical complications up to 1 year; and (3) independent risk factors for prosthetic joint infections (PJIs).A retrospective review was conducted using a national, all-payer database for patients undergoing primary TKA from January 2010 to April 2020 ( = 1.97 million). Patients diagnosed with RA were then separated into at least 1-year users of biologic ( = 3,092), nonbiologic (28,299), or dual ( = 10,949) therapy. Bivariate analyses were utilized to assess for 90-day medical and up to 1-year surgical outcomes. Additionally, multivariate regression models were utilized to assess for independent risk factors.The incidence and odds ratio for medical/surgical outcomes were equivocal among the biologic, nonbiologic, and recipients receiving both types of therapy ( > 0.061). No differences were observed between the type of therapy as additional risk factors for infection ( > 0.505). However, glucocorticoids at 90 days and alcohol abuse, diabetes mellitus, obesity, as well as tobacco use were identified as additional risk factors for PJI( < 0.036).No appreciable differences in medical or surgical outcomes were associated with the independent use of biologic, nonbiologic, or recipients of both types of therapy in patients with RA. Additionally, alcohol abuse, diabetes mellitus, glucocorticoids, obesity, and tobacco use conferred an increased risk of PJI. These results can serve as an adjunct to current practice guidelines.
超过 25%的类风湿关节炎 (RA) 患者预计在其一生中需要进行关节置换。鉴于其免疫抑制作用,目前的实践指南建议在全髋关节置换术前 1 周停止使用生物制剂。大多数患者都在接受包括生物制剂和非生物制剂的治疗方案;然而,在全膝关节置换术 (TKA) 中,这些治疗方法的个体影响尚不清楚。因此,我们试图比较接受 TKA 的 RA 患者中使用生物制剂、非生物制剂和同时使用这两种治疗方法的患者。我们专门评估了:(1)90 天内的医疗并发症;(2)1 年内的手术并发症;(3)人工关节感染 (PJI) 的独立危险因素。我们使用全国范围内的所有支付者数据库,对 2010 年 1 月至 2020 年 4 月期间接受初次 TKA 的患者进行了回顾性研究( = 197 万)。然后,将诊断为 RA 的患者分为至少使用 1 年生物制剂( = 3092 人)、非生物制剂(28299 人)或同时使用两种药物( = 10949 人)的患者。使用双变量分析评估 90 天的医疗和长达 1 年的手术结果。此外,还使用多变量回归模型评估独立的危险因素。在生物制剂、非生物制剂和同时使用这两种药物的患者中,医疗/手术结果的发生率和优势比并无差异( > 0.061)。在感染的额外危险因素方面,也未观察到治疗类型之间的差异( > 0.505)。然而,90 天时使用糖皮质激素、酗酒、糖尿病、肥胖以及吸烟被确定为 PJI 的额外危险因素( < 0.036)。在 RA 患者中,单独使用生物制剂、非生物制剂或同时使用这两种药物,其医疗或手术结果没有明显差异。此外,酗酒、糖尿病、糖皮质激素、肥胖和吸烟会增加 PJI 的风险。这些结果可以作为当前实践指南的补充。